BACKGROUND: Information about the cost-effectiveness of early intervention programmes for first-episode psychosis is limited. AIMS: To evaluate the cost-effectiveness of an intensive early-intervention programme (called OPUS) (trial registration NCT00157313) consisting of enriched assertive community treatment, psychoeducational family treatment and social skills training for individuals with first-episode psychosis compared with standard treatment. METHOD: An incremental cost-effectiveness analysis of a randomised controlled trial, adopting a public sector perspective was undertaken. RESULTS: The mean total costs of OPUS over 5 years (€123,683, s.e. = 8970) were not significantly different from that of standard treatment (€148,751, s.e. = 13073). At 2-year follow-up the mean Global Assessment of Functioning (GAF) score in the OPUS group (55.16, s.d. = 15.15) was significantly higher than in standard treatment group (51.13, s.d. = 15.92). However, the mean GAF did not differ significantly between the groups at 5-year follow-up (55.35 (s.d. = 18.28) and 54.16 (s.d. = 18.41), respectively). Cost-effectiveness planes based on non-parametric bootstrapping showed that OPUS was less costly and more effective in 70% of the replications. For a willingness-to-pay up to €50,000 the probability that OPUS was cost-effective was more than 80%. CONCLUSIONS: The incremental cost-effectiveness analysis showed that there was a high probability of OPUS being cost-effective compared with standard treatment.
RCT Entities:
BACKGROUND: Information about the cost-effectiveness of early intervention programmes for first-episode psychosis is limited. AIMS: To evaluate the cost-effectiveness of an intensive early-intervention programme (called OPUS) (trial registration NCT00157313) consisting of enriched assertive community treatment, psychoeducational family treatment and social skills training for individuals with first-episode psychosis compared with standard treatment. METHOD: An incremental cost-effectiveness analysis of a randomised controlled trial, adopting a public sector perspective was undertaken. RESULTS: The mean total costs of OPUS over 5 years (€123,683, s.e. = 8970) were not significantly different from that of standard treatment (€148,751, s.e. = 13073). At 2-year follow-up the mean Global Assessment of Functioning (GAF) score in the OPUS group (55.16, s.d. = 15.15) was significantly higher than in standard treatment group (51.13, s.d. = 15.92). However, the mean GAF did not differ significantly between the groups at 5-year follow-up (55.35 (s.d. = 18.28) and 54.16 (s.d. = 18.41), respectively). Cost-effectiveness planes based on non-parametric bootstrapping showed that OPUS was less costly and more effective in 70% of the replications. For a willingness-to-pay up to €50,000 the probability that OPUS was cost-effective was more than 80%. CONCLUSIONS: The incremental cost-effectiveness analysis showed that there was a high probability of OPUS being cost-effective compared with standard treatment.
Authors: Kelly K Anderson; Ross Norman; Arlene G MacDougall; Jordan Edwards; Lena Palaniyappan; Cindy Lau; Paul Kurdyak Journal: Can J Psychiatry Date: 2018-03-21 Impact factor: 4.356
Authors: Delbert G Robinson; Nina R Schooler; Robert A Rosenheck; Haiqun Lin; Kyaw J Sint; Patricia Marcy; John M Kane Journal: Psychiatr Serv Date: 2019-05-14 Impact factor: 3.084
Authors: Linda Kerkemeyer; Jürgen Wasem; Anja Neumann; Werner Brannath; Benjamin Mester; Jürgen Timm; Thomas Wobrock; Claudia Bartels; Peter Falkai; Janine Biermann Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-08-08 Impact factor: 5.270
Authors: Michael Groff; Eric Latimer; Ridha Joober; Srividya N Iyer; Norbert Schmitz; Sherezad Abadi; Amal Abdel-Baki; Nicola Casacalenda; Howard C Margolese; G Eric Jarvis; Ashok Malla Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306
Authors: Yvonne B Suijkerbuijk; Frederieke G Schaafsma; Joost C van Mechelen; Anneli Ojajärvi; Marc Corbière; Johannes R Anema Journal: Cochrane Database Syst Rev Date: 2017-09-12
Authors: Robert Rosenheck; Douglas Leslie; Kyaw Sint; Haiqun Lin; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Joanne Severe; Agnes Rupp; Michael Schoenbaum; John M Kane Journal: Schizophr Bull Date: 2016-01-31 Impact factor: 9.306